Vα14 NKT cell-mediated anti-tumor responses and their clinical application

Springer Seminars in Immunopathology

Volumn 27, Issue 1, 2005, Pages 65-74

  Seino, Ken Ichiro ^a   Fujii, Shin Ichiro ^a   Harada, Michishige ^a   Motohashi, Shinichiro ^b   Nakayama, Toshinori ^b   Fujisawa, Takehiko ^b   Taniguchi, Masaru ^a  

^a RIKEN Center for Integrative Medical Sciences   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

GalCer; Cancer; Glycolipid antigen; Immunotherapy; V 14 NKT cells

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALPHA GALACTOSYLCERAMIDE; CANCER VACCINE; LIGAND; TUMOR ANTIGEN; ALPHA-GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; IMMUNOGLOBULIN RECEPTOR; NATURAL KILLER CELL ACTIVATING RECEPTORS;

CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL STIMULATION; CELL TYPE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH1 CELL; TUMOR IMMUNITY; ANIMAL; CYTOTOXICITY; IMMUNOLOGY; NEOPLASM; PHYSIOLOGY;

ANIMALS; CLINICAL TRIALS; CYTOTOXICITY, IMMUNOLOGIC; GALACTOSYLCERAMIDES; HUMANS; KILLER CELLS, NATURAL; NEOPLASMS; RECEPTORS, IMMUNOLOGIC;

EID: 21344456790     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00281-004-0194-y     Document Type: Review

References (47)

1. Taniguchi M, Harada M, Kojo S, et al (2003) The regulatory role of Vα14NKT cells in innate and acquired immune response. Annu Rev Immunol 21:483
2. Kawano T, Cui J, Koezuka Y, et al (1997) CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278:1626
3. + T lymphocytes. Science 268:863
4. Kawano T, Cui J, Koezuka Y, et al (1998) Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc Natl Acad Sci USA 95:5690
5. +Vα24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 97:2067
6. Nakagawa R, Nagafune I, Tazunoki Y, et al (2001) Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α-galactosylceramide in mice. J Immunol 166:6578
7. Brigl M, Bry L, Kent SC, et al (2003) Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 4:1230
8. Gumperz JE, Roy C, Makowska A, et al (2000) Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12:211
9. Kawano T, Nakayama T, Kamada N, et al (1999) Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells. Cancer Res 59:5102
10. Zhou D, Cantu C 3rd, Sagiv Y, et al (2004) Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 303:523
11. Kamada N, Iijima H, Kimura K, et al (2001) Crucial amino acid residues of mouse CD1d for glycolipid ligand presentation to V(α)14 NKT cells. Int Immunol 13:853
12. Kitamura H, Iwakabe K, Yahata T, et al (1999) The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin IL-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189:1121
13. +NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol 163:93
14. +T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 99:1259
15. Hayakawa Y, Takeda K, Yagita H, et al (2001) Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur J Immunol 31:1720
16. Smyth MJ, Cretney E, Takeda K, et al (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193:661
17. Vilches C, Parham P (2002) KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 20:217
18. Natarajan K, Dimasi N, Wang J, et al (2002) Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol 20:853
19. Maeda M, Lohwasser S, Yamamura T, et al (2001) Regulation of NKT cells by Ly49: analysis of primary NKT cells and generation of NKT cell line. J Immunol 167:4180
20. Chang CS, Brossay L, Kronenberg M, et al (1999) The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis. J Exp Med 189:483
21. Dhodapkar MV, Geller MD, Chang DH, et al (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197:1667
22. Metelitsa LS, Naidenko OV, Kant A, et al (2001) Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 167:3114
23. + natural killer T cells activated by α-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 99:229
24. + regulatory T cells suppress NKT cell functions. Cancer Res 63:4516
25. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 100:10902
26. Kronenberg M, Gapin L (2002) The unconventional lifestyle of NKT cells. Nat Rev Immunol 2:557
27. Terabe M, Matsui S, Noben-Trauth N, et al (2003) TGF-beta production and myeloid cell are an effector mechanism through which CD1d-restricted T cells block CTL-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198:1741
28. Terabe M, Matsui S, Noben-Trauth N, et al (2000) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1:515
29. Terabe M, Berzofsky JA (2004) Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16:157
30. + NKT cells by repeated stimulation with KRN7000. J Immunol Methods 285:197
31. Vliet HJ van der, Nishi N, Koezuka Y, et al (2001) Potent expansion of human natural killer T cells using α-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Methods 247:61
32. + NKT cells activated by α-glycosylceramide- pulsed monocyte-derived dendritic cells. J Immunol 164:4458
33. Gumperz JE, Miyake S, Yamamura T, et al (2002) Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195:625
34. Motohashi S, Kobayashi S, Ito T, et al (2002) Preserved IFN-gamma production of circulating Vα24 NKT cells in primary lung cancer patients. Int J Cancer 102:159
35. Tahir SM, Cheng O, Shaulov A, et al (2001) Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167:4046
36. Yanagisawa K, Seino K, Ishikawa Y, et al (2002) Impaired proliferative response of V α 24 NKT cells from cancer patients against α-galactosylceramide. J Immunol 168:6494
37. Fujii S, Shimizu K, Klimek V, et al (2003) Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol 122:617
38. Dhodapkar KM, Cirignano B, Chamian F, et al (2004) Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer 109:893
39. + natural killer T cells using α-galactosyl ceramide-pulsed dendritic cells. J Immunol Methods 272:147
40. Giaccone G, Punt CJ, Ando Y, et al (2002) A phase I study of the natural killer T-cell ligand α- galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702
41. Fujii S, Shimizu K, Kronenberg M, et al (2002) Prolonged IFN-gamma-producing NKT response induced with α- galactosylceramide-loaded DCs. Nat Immunol 3:867
42. Toura I, Kawano T, Akutsu Y, et al (1999) Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 163:2387
43. Akutsu Y, Nakayama T, Harada M, et al (2002) Expansion of lung Vα14 NKT cells by administration of α-galactosylceramide-pulsed dendritic cells. Jpn J Cancer Res 93:397
44. Ishikawa A, Motohashi S, Ishikawa E, et al (in press) A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res
45. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103:383
46. Taniguchi M, Seino K, Nakayama T (2003) The NKT cell system: bridging innate and acquired immunity. Nat Immunol 4:1164
47. Termeer C, Benedix F, Sleeman J, et al (2002) Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 195:99